FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282969316> ?p ?o ?g. }

• W4282969316 endingPage "CT542" @default.
• W4282969316 startingPage "CT542" @default.
• W4282969316 abstract "Abstract Except breast cancer and gastric cancer, HER2 gene amplification or overexpression is also expressed in other solid tumors, including but not limited to colorectal cancer (CRC), non-small cell lung cancer (NSCLC), gallbladder cancer, renal pelvis cancer and pancreatic cancer. The reports of immunotherapy combined with HER2-targeted therapy are limited. KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA4 interaction with CD80/CD86. KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes. Here the preliminary safety and efficacy results of KN046 in combination KN026 were reported in patients with locally advanced unresectable or metastatic other solid tumors who received ≥ 1 line prior systemic therapy. Methods: HER2-positive locally advanced unresectable or metastatic other solid tumors with progression after ≥ 1 line of prior systemic therapy were recruited, including 14 CRC patients, 4 NSCLC patients, 4 gallbladder cancer patients, 1 renal pelvis cancer patient and 1 pancreatic cancer patient. These patients were by KN046 (iv. 5 mg/kg Q3W) plus KN026 (iv. 30 mg/kg Q3W, loading on C1D1, D8) until progression, unacceptable toxicity, or patient withdrawal. Efficacy was assessed according to RECIST 1.1 Q6W. The primary endpoint was objective response rate (ORR). Results: As of the August 10th, 2021, 24 non-breast or non-gastric cancer patients with the median age of 56 years (range: 37-66) were enrolled. 20 and 24 patients were evaluable for overall response and safety, respectively. The ORR was 55.0% (11 of 20, 95% CI: 31.5-76.9). And the disease control rate (DCR) was 85.0% (17 of 20, 95% CI 62.1-96.8). The 6-month progression-free survival (PFS) rate was 84.1%. 11 CRC patients were evaluable for overall response. The ORR and DCR in CRC was 45.5% (5 of 11, 95% CI: 16.7-76.6) and 90.9% (10 of 11, 95% CI 58.7-99.8), respectively. Twenty of total 24(87.9%) patients suffered from treatment-related adverse events (TRAEs) of any grade. Total 4 of 24 (16.7%) patients had experienced ≥grade 3 TRAEs, including 4 cases related to KN046 and 3 cases related to KN026. The most common (≥10%) TRAEs were infusion related reaction (29.2%), diarrhea (19.4%), alanine aminotransferase increased (16.7%), aspartate aminotransferase increased (16.7%), vomiting(12.5%) and decreased appetite (12.5%). No treatment-related deaths were observed. Conclusion: This chemotherapy-free regimen of KN046 in combination with KN026 has shown promising clinical efficacy and manageable toxicity in HER2-positive non-breast and non-gastric solid tumors with ≥ 1 line prior systemic therapy. The trial is currently ongoing. ClinicalTrials.gov Number, NCT04521179 Citation Format: Jifang Gong, Lei Chen, Meili Sun, Yanming Zhang, Jieer Ying, Xiangcai Wang, Mingli Ni, Zhixiang Zhuang, Baohong Guo, Long Xiao, Summer Xia, Lin Shen. Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT542." @default.
• W4282969316 created "2022-06-17" @default.
• W4282969316 creator A5002430497 @default.
• W4282969316 creator A5003464401 @default.
• W4282969316 creator A5006373750 @default.
• W4282969316 creator A5006511913 @default.
• W4282969316 creator A5010738468 @default.
• W4282969316 creator A5018224589 @default.
• W4282969316 creator A5030200922 @default.
• W4282969316 creator A5046280394 @default.
• W4282969316 creator A5048541371 @default.
• W4282969316 creator A5054433237 @default.
• W4282969316 creator A5085661325 @default.
• W4282969316 creator A5090872533 @default.
• W4282969316 date "2022-06-15" @default.
• W4282969316 modified "2023-10-17" @default.
• W4282969316 title "Abstract CT542: Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid cancer" @default.
• W4282969316 doi "https://doi.org/10.1158/1538-7445.am2022-ct542" @default.
• W4282969316 hasPublicationYear "2022" @default.
• W4282969316 type Work @default.
• W4282969316 citedByCount "0" @default.
• W4282969316 crossrefType "journal-article" @default.
• W4282969316 hasAuthorship W4282969316A5002430497 @default.
• W4282969316 hasAuthorship W4282969316A5003464401 @default.
• W4282969316 hasAuthorship W4282969316A5006373750 @default.
• W4282969316 hasAuthorship W4282969316A5006511913 @default.
• W4282969316 hasAuthorship W4282969316A5010738468 @default.
• W4282969316 hasAuthorship W4282969316A5018224589 @default.
• W4282969316 hasAuthorship W4282969316A5030200922 @default.
• W4282969316 hasAuthorship W4282969316A5046280394 @default.
• W4282969316 hasAuthorship W4282969316A5048541371 @default.
• W4282969316 hasAuthorship W4282969316A5054433237 @default.
• W4282969316 hasAuthorship W4282969316A5085661325 @default.
• W4282969316 hasAuthorship W4282969316A5090872533 @default.
• W4282969316 hasConcept C121608353 @default.
• W4282969316 hasConcept C126322002 @default.
• W4282969316 hasConcept C143998085 @default.
• W4282969316 hasConcept C2775930923 @default.
• W4282969316 hasConcept C2776694085 @default.
• W4282969316 hasConcept C2778822529 @default.
• W4282969316 hasConcept C2779984678 @default.
• W4282969316 hasConcept C2780210213 @default.
• W4282969316 hasConcept C526805850 @default.
• W4282969316 hasConcept C530470458 @default.
• W4282969316 hasConcept C71924100 @default.
• W4282969316 hasConceptScore W4282969316C121608353 @default.
• W4282969316 hasConceptScore W4282969316C126322002 @default.
• W4282969316 hasConceptScore W4282969316C143998085 @default.
• W4282969316 hasConceptScore W4282969316C2775930923 @default.
• W4282969316 hasConceptScore W4282969316C2776694085 @default.
• W4282969316 hasConceptScore W4282969316C2778822529 @default.
• W4282969316 hasConceptScore W4282969316C2779984678 @default.
• W4282969316 hasConceptScore W4282969316C2780210213 @default.
• W4282969316 hasConceptScore W4282969316C526805850 @default.
• W4282969316 hasConceptScore W4282969316C530470458 @default.
• W4282969316 hasConceptScore W4282969316C71924100 @default.
• W4282969316 hasIssue "12_Supplement" @default.
• W4282969316 hasLocation W42829693161 @default.
• W4282969316 hasOpenAccess W4282969316 @default.
• W4282969316 hasPrimaryLocation W42829693161 @default.
• W4282969316 hasRelatedWork W144521535 @default.
• W4282969316 hasRelatedWork W2037999876 @default.
• W4282969316 hasRelatedWork W2070780645 @default.
• W4282969316 hasRelatedWork W2139187298 @default.
• W4282969316 hasRelatedWork W2224319365 @default.
• W4282969316 hasRelatedWork W2411890706 @default.
• W4282969316 hasRelatedWork W2603750384 @default.
• W4282969316 hasRelatedWork W2979892935 @default.
• W4282969316 hasRelatedWork W3181412252 @default.
• W4282969316 hasRelatedWork W377899687 @default.
• W4282969316 hasVolume "82" @default.
• W4282969316 isParatext "false" @default.
• W4282969316 isRetracted "false" @default.
• W4282969316 workType "article" @default.